{
    "clinical_study": {
        "@rank": "112810", 
        "arm_group": [
            {
                "arm_group_label": "2-dose Primed Group", 
                "arm_group_type": "Experimental", 
                "description": "Adolescent subjects in this group received 2 doses of Twinrix Adult (720/20) (licensed as Ambirix in the EU) according to a 0, 6 months schedule in the primary study HAB-084 (208127/084)."
            }, 
            {
                "arm_group_label": "3-dose Primed Group", 
                "arm_group_type": "Experimental", 
                "description": "Adolescent subjects in this group received 3 doses of Twinrix Junior (360/10) according to a 0, 1, 6 months schedule in the primary study HAB-084 (208127/084)."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the long-term persistence of immunity to hepatitis A\n      and B in adults who were vaccinated 16-20 years earlier with the combined hepatitis A and\n      hepatitis B vaccine, Twinrix."
        }, 
        "brief_title": "Evaluation of the Long-term Hepatitis A and B Antibody Persistence in Healthy Adult Subjects, Primed 16 to 20 Years Earlier With GSK Biologicals' Combined Hepatitis A and B Vaccine, Twinrix\u00ae (SB208127) in Study HAB-084 (208127/084)", 
        "completion_date": {
            "#text": "October 2019", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Hepatitis B", 
            "Hepatitis A"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis B"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects who, in the opinion of the investigator, can and will comply with the\n             requirements of the protocol.\n\n          -  A male or female who received two/three doses of Twinrix according to his/her group\n             allocation in study HAB-084 (208127/084), and received no further dose of any\n             hepatitis A and/or B vaccine since then.\n\n          -  Written informed consent obtained from the subject.\n\n        Exclusion Criteria:\n\n          -  Chronic administration (defined as more than 14 days in total) of immunosuppressants\n             or other immune-modifying drugs within six months prior to study entry. Inhaled and\n             topical steroids are allowed.\n\n          -  Administration of long-acting immune-modifying drugs within six months prior to the\n             study entry.\n\n          -  Concurrently participating in another clinical study, at any time during the study\n             period, in which the subject has been or will be exposed to an investigational or a\n             non-investigational vaccine/product (pharmaceutical product or device).\n\n          -  Administration of any hepatitis A and/or B vaccine at any time since completion of\n             the primary vaccination series in HAB-084 (208127/084) study, including a challenge\n             dose of the study vaccine, as a part of the study procedures, during the long-term\n             persistence phase.\n\n          -  Documented history of hepatitis A or B disease since completion of the primary\n             vaccination series in HAB-084 (208127/084) study.\n\n          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, based on\n             medical history and physical examination (no laboratory testing required).\n\n          -  Administration of immunoglobulins within six months prior to study entry."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "64 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "180", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 8, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02135666", 
            "org_study_id": "117307", 
            "secondary_id": "2013-004586-13"
        }, 
        "intervention": {
            "arm_group_label": [
                "3-dose Primed Group", 
                "2-dose Primed Group"
            ], 
            "description": "At Years 16 - 20 after first dose of the primary vaccination in HAB-084 (208127/084) study.", 
            "intervention_name": "Blood sampling", 
            "intervention_type": "Procedure"
        }, 
        "intervention_browse": {
            "mesh_term": "Antibodies"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Twinrix", 
            "Long-term follow-up", 
            "Persistence", 
            "Hepatitis A", 
            "Antibody", 
            "Immunity", 
            "Hepatitis B", 
            "Combination vaccine", 
            "Adult"
        ], 
        "lastchanged_date": "May 29, 2014", 
        "location": {
            "contact": {
                "email": "GSKClinicalSupportHD@gsk.com", 
                "last_name": "US GSK Clinical Trials Call Center", 
                "phone": "877-379-3718"
            }, 
            "contact_backup": {
                "email": "GSKClinicalSupportHD@gsk.com", 
                "last_name": "EU GSK Clinical Trials Call Center", 
                "phone": "+44 (0) 20 8990 4466"
            }, 
            "facility": {
                "address": {
                    "city": "Hradec Kralove", 
                    "country": "Czech Republic", 
                    "zip": "500 01"
                }, 
                "name": "GSK Investigational Site"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Czech Republic"
        }, 
        "number_of_arms": "2", 
        "official_title": "Long-term Hepatitis A and B Antibody Persistence in Healthy Adult Subjects, Primed 16 to 20 Years Earlier With GSK Biologicals' Combined Hepatitis A and B Vaccine, Twinrix\u00ae (SB208127) in Study HAB-084 (208127/084)", 
        "overall_contact": {
            "email": "GSKClinicalSupportHD@gsk.com", 
            "last_name": "US GSK Clinical Trials Call Center", 
            "phone": "877-379-3718"
        }, 
        "overall_official": {
            "affiliation": "GlaxoSmithKline", 
            "last_name": "GSK Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "Belgium: Federal Agency for Medicines and Health Products, FAMHP", 
                "Czech Republic: State Institute for Drug Control"
            ]
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "October 2019", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Immunogenicity with respect to components of the study vaccine in terms of antibody titres", 
            "safety_issue": "No", 
            "time_frame": "At each long-term follow-up (LTFU) visit (16-20 years after the first dose of primary vaccination)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02135666"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Occurrence of Serious adverse events (SAEs)", 
            "safety_issue": "No", 
            "time_frame": "During the entire study period (Year 16-20)"
        }, 
        "source": "GlaxoSmithKline", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "GlaxoSmithKline", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}